580 related articles for article (PubMed ID: 33215952)
21. Emerging targeted therapies and strategies to overcome resistance in biliary tract cancers.
Demir T; Moloney C; Mahalingam D
Crit Rev Oncol Hematol; 2024 Jul; 199():104388. PubMed ID: 38754771
[TBL] [Abstract][Full Text] [Related]
22. Current Role and Future Perspectives of Immunotherapy and Circulating Factors in Treatment of Biliary Tract Cancers.
Conci S; Catalano G; Roman D; Zecchetto C; Lucin E; De Bellis M; Tripepi M; Guglielmi A; Milella M; Ruzzenente A
Int J Med Sci; 2023; 20(7):858-869. PubMed ID: 37324191
[TBL] [Abstract][Full Text] [Related]
23. Immune checkpoint inhibitor therapy in biliary tract cancer (cholangiocarcinoma).
Jakubowski CD; Azad NS
Chin Clin Oncol; 2020 Feb; 9(1):2. PubMed ID: 32008328
[TBL] [Abstract][Full Text] [Related]
24. Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future.
Rizzo A; Ricci AD; Cusmai A; Acquafredda S; De Palma G; Brandi G; Palmiotti G
Curr Oncol; 2022 Jan; 29(2):551-564. PubMed ID: 35200550
[TBL] [Abstract][Full Text] [Related]
25. IDH Inhibitors and Immunotherapy for Biliary Tract Cancer: A Marriage of Convenience?
Brandi G; Rizzo A
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142781
[TBL] [Abstract][Full Text] [Related]
26. Biliary Tract Cancer: State of the Art and potential role of DNA Damage Repair.
Lamarca A; Barriuso J; McNamara MG; Valle JW
Cancer Treat Rev; 2018 Nov; 70():168-177. PubMed ID: 30218788
[TBL] [Abstract][Full Text] [Related]
27. The state of therapy modalities in clinic for biliary tract cancer.
Chen W; Hu Z; Song J; Wu Y; Zhang B; Zhang L
Front Biosci (Landmark Ed); 2022 Jun; 27(6):185. PubMed ID: 35748261
[TBL] [Abstract][Full Text] [Related]
28. Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation.
Athauda A; Fong C; Lau DK; Javle M; Abou-Alfa GK; Morizane C; Steward K; Chau I
Cancer Treat Rev; 2020 Jun; 86():101998. PubMed ID: 32203843
[TBL] [Abstract][Full Text] [Related]
29. Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes.
Chen X; Wang D; Liu J; Qiu J; Zhou J; Ying J; Shi Y; Wang Z; Lou H; Cui J; Zhang J; Liu Y; Zhao F; Pan L; Zhao J; Zhu D; Chen S; Li X; Li X; Zhu L; Shao Y; Shu Y
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795005
[TBL] [Abstract][Full Text] [Related]
30. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
Dafni U; Tsourti Z; Vervita K; Peters S
Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy: A Sharp Curve Turn at the Corner of Targeted Therapy in the Treatment of Biliary Tract Cancers.
Al Mahmasani L; Harding JJ; Abou-Alfa G
Hematol Oncol Clin North Am; 2024 Jun; 38(3):643-657. PubMed ID: 38423933
[TBL] [Abstract][Full Text] [Related]
32. Hepatobiliary cancers and immunotherapy: where are we now and where are we heading?
Zayac A; Almhanna K
Transl Gastroenterol Hepatol; 2020; 5():8. PubMed ID: 32190776
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future.
Blair AB; Murphy A
Curr Probl Cancer; 2018; 42(1):49-58. PubMed ID: 29501212
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapy in Biliary Tract Cancers: Where Are We?
Kalyan A; Khosla H; Kim RD
Curr Oncol Rep; 2022 Dec; 24(12):1821-1828. PubMed ID: 36192517
[TBL] [Abstract][Full Text] [Related]
35. An update on the use of immunotherapy in patients with colorectal cancer.
Nguyen M; Tipping Smith S; Lam M; Liow E; Davies A; Prenen H; Segelov E
Expert Rev Gastroenterol Hepatol; 2021 Mar; 15(3):291-304. PubMed ID: 33138649
[No Abstract] [Full Text] [Related]
36. The emerging role of immunotherapy in biliary tract cancer: a review of new evidence and predictive biomarkers.
Giorgione R; Risaliti M; Bartolini I; Rossi G; Pillozzi S; Muiesan P; Taddei A; Antonuzzo L
Immunotherapy; 2022 May; 14(7):567-576. PubMed ID: 35382560
[TBL] [Abstract][Full Text] [Related]
37. Next-generation sequencing-guided molecular-targeted therapy and immunotherapy for biliary tract cancers.
Zhang W; Shi J; Wang Y; Zhou H; Zhang Z; Han Z; Li G; Yang B; Cao G; Ke Y; Zhang T; Song T; QiangLi
Cancer Immunol Immunother; 2021 Apr; 70(4):1001-1014. PubMed ID: 33095329
[TBL] [Abstract][Full Text] [Related]
38. Advances in the systemic treatment of therapeutic approaches in biliary tract cancer.
Mirallas O; López-Valbuena D; García-Illescas D; Fabregat-Franco C; Verdaguer H; Tabernero J; Macarulla T
ESMO Open; 2022 Jun; 7(3):100503. PubMed ID: 35696747
[TBL] [Abstract][Full Text] [Related]
39. News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors.
Melaiu O; Lucarini V; Giovannoni R; Fruci D; Gemignani F
Semin Cancer Biol; 2022 Feb; 79():18-43. PubMed ID: 32659257
[TBL] [Abstract][Full Text] [Related]
40. The role of novel biologics in biliary cancers.
Jordan E; Braghiroli MF; Lowery MA
Minerva Gastroenterol Dietol; 2016 Dec; 62(4):325-339. PubMed ID: 27576672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
